Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.30 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10576164 | 0.85 | CA2 (0.32) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL9392724 | 0.83 | CHRM1 (0.41) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL9705800 | 0.83 | ENPEP (0.40) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL27667016 | 0.80 | MGAM (0.33) | — | |
| SCHEMBL12851375 | 0.78 | GPR84 (0.41) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL11587400 | 0.76 | CHRM1 (0.55) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL65535 | 0.76 | CHRM1 (0.36) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL6922740 | 0.76 | GPR84 (0.44) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL223020 | 0.76 | CHRM1 (0.55) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL28559675 | 0.75 | ALDH1A1 (0.41) | TDP1TSHRLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117551026-A | Preparation method and application of nicardipine hydrochloride impurity | 成都地奥九泓制药厂 | 2024-02-13 | — | — | CN | disclosed |
| WO-2015189433-A1 | PYRIDAZINONES FOR THE TREATMENT OF CANCER | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-17 | — | — | WO | disclosed |
| EP-2955182-A1 | Pyridazinones for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-16 | — | — | EP | disclosed |
| EP-1765830-B1 | MITOTIC KINESIN INHIBITORS | MERCK SHARP & DOHME (US) | 2010-09-22 | — | — | EP | disclosed |
| US-20100081839-A1 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA LABORATORIES LTD. (IN) | 2010-04-01 | — | — | US | disclosed |
| US-7632833-B2 | Anticancer agents | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-2114957-A2 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA Laboratories Limited (IN) | 2009-11-11 | — | — | EP | disclosed |
| US-20080287414-A1 | Mitotic Kinesin Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080188663-A1 | Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I | IPCA LABORATORIES LIMITED (IN) | 2008-08-07 | — | — | US | disclosed |
| WO-2008093357-A2 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA LABORATORIES LIMITED (IN) | 2008-08-07 | — | — | WO | disclosed |
| EP-1765830-A1 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006023083-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006007491-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| EP-0392037-A1 | Process for the preparation of syn-aminothiazolyl and syn-amino-oxazolyl derivatives of alkoxyiminoacetic acids | TECHNOLOGITCHEN KOMBINAT ZA PROMISHLENA MIKROBIOLOGIA (BG) | 1990-10-17 | — | — | EP | disclosed |
| US-4806534-A | SMOOTH MUSCLE RELAXANT, CALCIUM ANTAGONIST | RECORDATI S.A., CHEMICAL & PHARMACEUTICAL COMPANY (CH) | 1989-02-21 | — | — | US | disclosed |
| US-4064166-A | FROM CHLOROACETONE OR 3-CHLOROACETYLACETONE AND A SULFONATED POLYPHENOL | INTERNATIONAL TELEPHONE AND TELEGRAPH CORPORATION (US) | 1977-12-20 | — | — | US | disclosed |
| US-3970691-A | Etherification of bark extracts | INTERNATIONAL TELEPHONE AND TELEGRAPH CORPORATION (US) | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081839-A1 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | VKORC1, VKORC1L1, PTGER1 | CHRM1 720/4885AKR1A1 134/4885CHRM3 1065/4885 |
| US-20080188663-A1 | Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I | CYP2S1, CYP2F1, VKORC1L1 | CHRM1 899/4885AKR1A1 1060/4885CHRM3 968/4885 |
| US-20080287414-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF18B | CHRM1 4803/4885AKR1A1 837/4885CHRM3 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.